AstraZeneca's Baxdrostat met the primary and all secondary endpoints in BaxHTN Phase III trial
Baxdrostat demonstrated a statistically significant and clinically meaningful reduction of systolic blood pressure compared with placebo
Baxdrostat demonstrated a statistically significant and clinically meaningful reduction of systolic blood pressure compared with placebo
Star Health Insurance is modernising its claims ecosystem to be future-ready
This collaboration ensures that patients receive comprehensive care, including emotional and psychological support throughout their fertility journey
Bisoprolol is a highly cardioselective beta-1 adrenergic blocker used to manage high blood pressure,
The company's first-ever corporate-level submission to EcoVadis builds on years of operational and environmental excellence
30th Lab in Thyrocare’s expanding network to bring advanced, affordable diagnostics in Bihar and beyond
Subscribe To Our Newsletter & Stay Updated